Anatomic Stage III Breast Cancer AJCC v8 Active Not Recruiting Phase 2 Trials for Mirvetuximab Soravtansine (DB12489)

IndicationStatusPhase
DBCOND0109625 (Anatomic Stage III Breast Cancer AJCC v8)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03106077Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast CancerTreatment